TELESTA THERAPEUTICS INC T.TST

How does a shares right plan help an investor in a takeover?

[wussy]

https://business.financialpost.com/2014/07/30/augusta-decision-is-no-prescription-for-use-of-poison-pills/

Just wondering
GLTAL
Wussy

[IoftheLynchMob]

Wussy, having lived through Bioniche pharma and watched  Bioniche Animal health from the sidelines you should worry, and worry hard!  Shareholders will lose Urocidin without even knowing it if they are not diligent and perhaps militant. An effort is already underway to swipe a 2 billion dollar property from shareholder's hands. It will be relentless in the coming weeks, if not days

[ragingbull1327]

The best thing a potential buyer could do is make an offer that stifles any other potential offer.   I hope they bid low though, and create an auction.   These people have wasted so many years waiting for a decent economic environment to do this, regardless of who they could have helped in the interim.    It's all a big joke that's lacking a punch line.   A price

[ragingbull1327]

Do the math.   I don't care how many shares anyone holds.   No one is getting WEALTHY off of 0.35. No one.  

[IoftheLynchMob]

The share price has no relationship to the underlying value of the company. In fact a case could be made that the sub 50 mil market cap only reflects the vaccine plant, Econiche and associated patents. Of course some will try and convince shareholders that a multiple of 1.5 or 2 x the current SP is a very reasonable offer. An independent agent may even be hired, at your expense, to validate and

[rgonlyfactspls]

Hi loftheLynchmob re: your statement... "An effort is already underway to swipe a 2 billion dollar property from shareholder's hands." ---- A strong and rather definitive appearing statement. Possibly you can elaborate / be more specific regarding this "effort already underway"? Thank you in advance, rg

[IoftheLynchMob]

RGonlyfacts, I have no evidence to back up this claim, but you would be naive to think that a 45 mil market cap biotech, with a pending submission for FDA approval, is not at this moment being targeted for a lowball takeout. Blend in the long and sordid history of shareholder discontent and Bioniche is as ripe as the rotting banana on your countertop.

[rgonlyfactspls]

loftheLynchmob....Thanks for clarifying. And, your point is taken (even if statement made unsubstantiated). rg

[IoftheLynchMob]

Rgonly, when you have a free moment run a google search on the cost of a p3 cancer trial. Not necessarily bladder cancer but a general search. I think that you will find the costs ranging from 75-300 mil, all inclusive. In fact there have been several P2 trials that have exceeded 100 mil in cost. Then look at Bioniche and its marvellous valuation. with no need for further clinical trials, a niche

[IoftheLynchMob]

RGonly, I forgot to mention that by the time your P3 is completed and ready for submission, assuming that  the FDA allows it to complete, it is now 2018. Urocidin will be generating its Billionth dollar in revenue as you are signing off on your application.

[IoftheLynchMob]

RGonlyfacts, before I head back from lunch! take another 5 minutes and google the cost of setting up in house production of a cancer treatment, chemo or biologic, or the cost of validating 3rd party manufacturing for your new cancer drug. The capital outlay is nearly the cost of another P3, assuming you are fortunate enough to complete it before the FDA shuts it down. surprisingly Bioniche just